BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://murmitoyen.com/events/vanille/udem/
X-WR-TIMEZONE:America/Montreal
BEGIN:VEVENT
UID:69df1f04d3cfb
DTSTAMP:20260415T011548
DTSTART:20141119T110000
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20141119T123000
URL:https://murmitoyen.com/events/vanille/udem/detail/470553
LOCATION:Université de Montréal - Pavillon J.-Armand-Bombardier\, 5155\, 
 chemin de la rampe \, Montréal\, QC\, Canada\, H3T 2B2
SUMMARY:Conférence du Professeur Patrick Gunning (Toronto)
DESCRIPTION:Titre : Targeting STAT3 Protein-Protein Interactions with Small
  Molecules:Therapeutics for Treating Cancer.Endroit : Pavillon J.-A.-Bomba
 rdier\, salle 1035 à 11 hHôte : Professeure Andreea SchmitzerLa confére
 nce sera prononcée (en anglais) par le professeur Patrick Gunning\, du d
 épartement des sciences chimique et physique de l'University of Toronto-M
 ississauga.Résumé : STAT3 protein-protein interactions are essential for
  transducing signals from extracellular stimuli\, but also functions as a 
 nuclear transcription factor required for regulating genes involved in pro
 liferation\, apoptosis\, angiogenesis and invasion\, in addition to genes 
 encoding cytokines\,chemokines and growth factors. In contrast to the tran
 sient nature of STAT3 activation in normal cells\, many humancancers\, inc
 luding breast\, prostate\, ovarian\, brain and multiple myeloma (MM) harbo
 r constitutive STAT3 activity. STAT3 downstream target genes are critical 
 to the dysregulated biological processes that promote tumor cell growth\, 
 survival and induce chemoresistance\, thus targeting STAT3 signaling repre
 sents an important therapeutic target in cancer therapy.We have rationally
  designed and developed STAT3 inhibitors that disrupt transcriptionaly act
 ive STAT3­-STAT3 homo-dimers\, suppress STAT3 activation (phosphorylation
 )\, inhibit STAT3-target gene expression (c-Myc\, Bcl-xL\, survivin) and p
 otently induce apoptosis in tumor cells harboring aberrant STAT3 activity.
  Moreover\, lead compound SH-4-54\, a small molecule inhibitor\, induced s
 trong antitumor effects on human breast cancer\, multiple myeloma and brai
 n cancer preclinical tumor models. Most notably\, SH-4-54 is orally bioava
 ilable\, strongly inhibiting the growth of tumors\, identifying it as a mo
 st potent orally bioavailableSTAT3-targeting inhibitor.Information supplé
 mentaireAnnonce PDF de la conférence
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Montreal
X-LIC-LOCATION:America/Montreal
END:VTIMEZONE
END:VCALENDAR